Case report: Tocilizumab for hypersensitivity reaction after oxaliplatin in a patient with NK/T-cell lymphoma

被引:0
作者
Liao, Juanyan [1 ]
Jiang, Ming [2 ]
机构
[1] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Canc Ctr, Dept Head & Neck Oncol, Chengdu, Sichuan, Peoples R China
关键词
tocilizumab; hypersensitivity reaction; oxaliplatin; NK/T-cell lymphoma; IL-6; CYTOKINE RELEASE SYNDROME; RECEPTOR;
D O I
10.3389/fphar.2024.1471038
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Oxaliplatin-induced hypersensitivity reactions (HSRs) are commonly encountered in first-line therapies for various malignancies. Recent research indicates that these reactions can include cytokine release reactions (CRRs), which are characterized by a marked increase in interleukin-6 (IL-6) levels, sometimes rising as much as 40-fold. Standard management strategies for HSRs typically involve desensitization protocols and routine treatments. However, these conventional approaches may be insufficient for managing CRRs. Preliminary studies suggest that tocilizumab, an IL-6 receptor (IL-6R) antagonist, may play a crucial role in mitigating CRRs. In our case, a 65-year-old male with stage IV extranodal NK/T-cell lymphoma developed a severe HSR on day 1 following the infusion of oxaliplatin during his fourth chemotherapy cycle. This reaction was marked by a substantial increase in IL-6 levels. Despite the administration of standard treatments, including epinephrine and corticosteroids, the patient required ventilatory support and vasopressors on day 1. On day 2, tocilizumab was administered, resulting in a rapid and significant reduction in IL-6 levels. Subsequently, the patient's symptoms, including fever, dyspnea, and hypotension, resolved, and he was discharged on day 5. This case demonstrates that tocilizumab can be an effective intervention in managing severe HSRs associated with CRRs. To our knowledge, this is the first reported instance of tocilizumab successfully salvaging a patient experiencing oxaliplatin-induced HSR. Nevertheless, further research is required to validate the efficacy of tocilizumab in treating oxaliplatin-induced HSRs.
引用
收藏
页数:5
相关论文
共 21 条
  • [1] Clinical features and severity grading of anaphylaxis
    Brown, SGA
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 114 (02) : 371 - 376
  • [2] Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review)
    Chen, Jia-Jie
    Zhang, Li-Na
    Hou, Hu
    Xu, Lingqing
    Ji, Kunmei
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (01)
  • [3] The Immunology of Macrophage Activation Syndrome
    Crayne, Courtney B.
    Albeituni, Sabrin
    Nichols, Kim E.
    Cron, Randy Q.
    [J]. FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [4] Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review
    Faisal, ALMuhizi
    De las Vecillas Sanchez, Leticia
    Gilbert, Lucy
    Copaescu, Ana M.
    Isabwe, Ghislaine A. C.
    [J]. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2022, 62 (03) : 534 - 547
  • [5] Interleukin-6: designing specific therapeutics for a complex cytokine
    Garbers, Christoph
    Heink, Sylvia
    Korn, Thomas
    Rose-John, Stefan
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (06) : 395 - 412
  • [6] IL-6/sIL-6R trans-signalling, but not TNF-α induced angiogenesis in a HUVEC and synovial cell co-culture system
    Hashizume, Misato
    Hayakawa, Naohiko
    Suzuki, Miho
    Mihara, Masahiko
    [J]. RHEUMATOLOGY INTERNATIONAL, 2009, 29 (12) : 1449 - 1454
  • [7] Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells
    Heink, Sylvia
    Yogev, Nir
    Garbers, Christoph
    Herwerth, Marina
    Aly, Lilian
    Gasperi, Christiane
    Husterer, Veronika
    Croxford, Andrew L.
    Moeller-Hackbarth, Katja
    Bartsch, Harald S.
    Sotlar, Karl
    Krebs, Stefan
    Regen, Tommy
    Blum, Helmut
    Hemmer, Bernhard
    Misgeld, Thomas
    Wunderlich, Thomas F.
    Hidalgo, Juan
    Oulcka, Mohamed
    Rose-John, Stefan
    Schmidt-Supprian, Marc
    Waisman, Ari
    Korn, Thomas
    [J]. NATURE IMMUNOLOGY, 2017, 18 (01) : 74 - 85
  • [8] Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization
    Jimenez-Rodriguez, Teodorikez-Wilfox
    de las Vecillas, Leticia
    Labella, Marina
    Lynch, Donna-Marie
    Besz, Kylie Marie
    Marquis, Kathleen
    Burgos, Amparo
    Gomis, Victor Soriano
    Lozano, Inmaculada
    Anton, Rosa Ana Montoyo
    de la Calle, Francisco Marco
    Delgado, Maria Purificacion Gonzalez
    Gutierrez, Aurora
    Montenegro, Estefania
    Rodriguez, Fernando
    Sanchez, Francisco Javier Fernandez
    Castells, Mariana
    [J]. ALLERGY, 2024, 79 (03) : 679 - 689
  • [9] Current concepts in the diagnosis and management of cytokine release syndrome
    Lee, Daniel W.
    Gardner, Rebecca
    Porter, David L.
    Louis, Chrystal U.
    Ahmed, Nabil
    Jensen, Michael
    Grupp, Stephan A.
    Mackall, Crystal L.
    [J]. BLOOD, 2014, 124 (02) : 188 - 195
  • [10] IL-6/IL-6 receptor system and its role in physiological and pathological conditions
    Mihara, Masahiko
    Hashizume, Misato
    Yoshida, Hiroto
    Suzuki, Miho
    Shiina, Masashi
    [J]. CLINICAL SCIENCE, 2012, 122 (3-4) : 143 - 159